SET and acute lymphoblastic leukemia: Next, we investigated the in vitro efficacy of the SET inhibitor OP449 on T-ALL cell lines and demonstrated a dose-dependent increase in PP2A activity and a decrease in cell viability and survival, supporting previous findings regarding the oncogenic properties of SET in hematopoietic malignancies [16, 18, 32, 34].